{"id":30731,"date":"2017-04-07T17:36:14","date_gmt":"2017-04-07T15:36:14","guid":{"rendered":"http:\/\/www.fedaiisf.it\/?p=30731"},"modified":"2017-04-07T18:06:41","modified_gmt":"2017-04-07T16:06:41","slug":"farmaci-loms-prequalifica-principio-attivo-generico-nuovi-anti-epatite","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/farmaci-loms-prequalifica-principio-attivo-generico-nuovi-anti-epatite\/","title":{"rendered":"Drugs: WHO prequalifies generic active ingredient for new anti-hepatitis drugs"},"content":{"rendered":"

"Sofosbuvir - recalls the WHO - is an essential ingredient for new highly effective drugs against hepatitis C"<\/em><\/p>\n

care of Filomena Fotia<\/a>\u00a0–\u00a0

\n
\n

For the first time, the World Health Organization (WHO) has prequalified a generic pharmaceutical active ingredient against hepatitis C: sofosbuvir. \u201cSofosbuvir<\/em> \u2013 recalls the WHO \u2013 it is an essential ingredient for highly effective new drugs against hepatitis C. <\/em><\/p>\n

\"RisultatiThe manufacturer for this prequalified active substance is Mylan Laboratories India<\/em>\u201c. With this operation, WHO explains, a quality source has been identified for generic producers interested in sofosbuvir.<\/p>\n

\u201cEvidently the problem is linked to the fact that whoever had the license to produce the generic sofobuvir could not produce enough. The prequalified company is not authorized to produce the drug but only the active ingredient, so that there is more for those who want to produce the generic<\/em>\u201c, explains to Adnkronos Salute the pharmacologist Silvio Garattini, director of Mario Negri.<\/p>\n

The objective of the operation is to facilitate access to anti-hepatitis C super-drugs by making them more accessible, as explained by the WHO, recalling that "competition from generics has already reduced prices in several countries: for example, in Egypt the cost of three months of treatment dropped from US$900 in 2015 to less than US$200 in 2016, and in Pakistan the same treatment now costs US$100<\/em>\u201c.<\/p>\n

\u201cData that is not surprising<\/em> \u2013 comments Garattini \u2013 since this product, which we still pay for in gold, actually costs nothing. Let's hope that the situation will clear up and the drug will become more accessible in our country as well<\/em>\u201c.<\/p>\n

Related news:\u00a0WHO prequalifies first generic active ingredient for hepatitis C medicines<\/span><\/a><\/p>\n

Medicines imported from abroad, new rules for personal use<\/a><\/span><\/p>\n

All-inclusive medical travel for the new Hepatitis C treatment<\/span><\/a><\/p>\n<\/div>\n

<\/div>\n<\/div>\n
<\/div>\n
<\/div>","protected":false},"excerpt":{"rendered":"

“Sofosbuvir – ricorda l’Oms – \u00e8 un ingrediente essenziale per i nuovi farmaci altamente efficaci contro l’epatite C” cura di Filomena Fotia\u00a0–\u00a07 aprile 2017 – MeteoWeb Per la prima volta l\u2019Organizzazione mondiale della sanit\u00e0 (Oms) ha prequalificato un ingrediente attivo farmaceutico generico contro l\u2019epatite C: il sofosbuvir. \u201cSofosbuvir \u2013 ricorda l\u2019Oms \u2013 \u00e8 un ingrediente …<\/p>","protected":false},"author":4,"featured_media":21124,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[31,91,29],"class_list":["post-30731","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-generici","tag-india","tag-prezzo-farmaci"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/30731","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=30731"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/30731\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/21124"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=30731"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=30731"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=30731"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}